- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
VRIO Analysis of Pfizer and AstraZeneca Marketing an Acquisition B
Posted by Zachary Edwards on Mar-22-2018
The VRIO Analysis of Pfizer and AstraZeneca Marketing an Acquisition B will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The Pfizer and AstraZeneca Marketing an Acquisition B VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.
Valuable
- The Pfizer and AstraZeneca Marketing an Acquisition B VRIO Analysis shows that the financial resources of Pfizer and AstraZeneca Marketing an Acquisition B are highly valuable as these help in investing into external opportunities that arise. These also help Pfizer and AstraZeneca Marketing an Acquisition B in combating external threats.
- According to the VRIO Analysis of Pfizer and AstraZeneca Marketing an Acquisition B, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
- The Pfizer and AstraZeneca Marketing an Acquisition B VRIO Analysis shows that Pfizer and AstraZeneca Marketing an Acquisition B's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of Pfizer and AstraZeneca Marketing an Acquisition B's products.
- According to the VRIO Analysis of Pfizer and AstraZeneca Marketing an Acquisition B, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for Pfizer and AstraZeneca Marketing an Acquisition B. These patents also provide Pfizer and AstraZeneca Marketing an Acquisition B with licensing revenue when it licenses these patents out to other manufacturers.
- The Pfizer and AstraZeneca Marketing an Acquisition B VRIO Analysis shows that Pfizer and AstraZeneca Marketing an Acquisition B’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for Pfizer and AstraZeneca Marketing an Acquisition B. It also ensures that promotion activities translate into sales as the products are easily available.
- According to the VRIO Analysis of Pfizer and AstraZeneca Marketing an Acquisition B, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
- The Pfizer and AstraZeneca Marketing an Acquisition B VRIO Analysis shows that the research and development at Pfizer and AstraZeneca Marketing an Acquisition B is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for Pfizer and AstraZeneca Marketing an Acquisition B. It is recommended that the research and development teams are improved, and costs are cut for these.
Rare
- The financial resources of Pfizer and AstraZeneca Marketing an Acquisition B are found to be rare according to the VRIO Analysis of Pfizer and AstraZeneca Marketing an Acquisition B. Strong financial resources are only possessed by a few companies in the industry.
- The local food products are found to be not rare as identified by Pfizer and AstraZeneca Marketing an Acquisition B VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as Pfizer and AstraZeneca Marketing an Acquisition B and inhibit competitive advantage. This means that the local food products result in competitive parity for Pfizer and AstraZeneca Marketing an Acquisition B. As this resource is valuable, Pfizer and AstraZeneca Marketing an Acquisition B can still make use of this resource.
- The employees of Pfizer and AstraZeneca Marketing an Acquisition B are a rare resource as identified by the VRIO Analysis of Pfizer and AstraZeneca Marketing an Acquisition B. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
- The patents of Pfizer and AstraZeneca Marketing an Acquisition B are a rare resource as identified by the Pfizer and AstraZeneca Marketing an Acquisition B VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows Pfizer and AstraZeneca Marketing an Acquisition B to use them without interference from the competition.
- The distribution network of Pfizer and AstraZeneca Marketing an Acquisition B is a rare resource as identified by the VRIO Analysis of Pfizer and AstraZeneca Marketing an Acquisition B. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of Pfizer and AstraZeneca Marketing an Acquisition B. These are also possessed by very few firms in the industry.
Imitable
- The financial resources of Pfizer and AstraZeneca Marketing an Acquisition B are costly to imitate as identified by the Pfizer and AstraZeneca Marketing an Acquisition B VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
- The local food products are not that costly to imitate as identified by the VRIO Analysis of Pfizer and AstraZeneca Marketing an Acquisition B. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by Pfizer and AstraZeneca Marketing an Acquisition B provide it with a temporary competitive advantage that competitors can too acquire in the long run.
- The employees of Pfizer and AstraZeneca Marketing an Acquisition B are also not costly to imitate as identified by the Pfizer and AstraZeneca Marketing an Acquisition B VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from Pfizer and AstraZeneca Marketing an Acquisition B by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of Pfizer and AstraZeneca Marketing an Acquisition B a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
- The patents of Pfizer and AstraZeneca Marketing an Acquisition B are very difficult to imitate as identified by the VRIO Analysis of Pfizer and AstraZeneca Marketing an Acquisition B. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
- The distribution network of Pfizer and AstraZeneca Marketing an Acquisition B is also very costly to imitate by competition as identified by the Pfizer and AstraZeneca Marketing an Acquisition B VRIO Analysis. This has been developed over the years gradually by Pfizer and AstraZeneca Marketing an Acquisition B. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.
Organisation
- The financial resources of Pfizer and AstraZeneca Marketing an Acquisition B are organised to capture value as identified by the VRIO Analysis of Pfizer and AstraZeneca Marketing an Acquisition B. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for Pfizer and AstraZeneca Marketing an Acquisition B.
- The Patents of Pfizer and AstraZeneca Marketing an Acquisition B are not well organised as identified by the Pfizer and AstraZeneca Marketing an Acquisition B VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if Pfizer and AstraZeneca Marketing an Acquisition B starts selling patented products before the patents expire.
- The distribution network of Pfizer and AstraZeneca Marketing an Acquisition B is organised as identified by the VRIO Analysis of Pfizer and AstraZeneca Marketing an Acquisition B. Pfizer and AstraZeneca Marketing an Acquisition B uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for Pfizer and AstraZeneca Marketing an Acquisition B.
From the VRIO Analysis of Pfizer and AstraZeneca Marketing an Acquisition B, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of Pfizer and AstraZeneca Marketing an Acquisition B is a competitive disadvantage. Research and Development is also a competitive disadvantage.
Warning! This article is only an example and cannot be used for research or reference purposes. If you need help with something similar, please submit your details here.
Dakshi Chandresh
5.0
Well satisfied with the outcomes of the paper. I think this service is better for scoring an A.
Robert Dani
5.0
The 7th semester has been completed and the 8th semester will start from next month. Then I’ll place orders frequently and post reviews here regularly.
Kata Oliver
5.0
The most reliable company that I ever visited. Got the assignment of 10,000 words and delighted with the relevancy of thoughts. I highly recommend this service!!
Khalil R Al-Battat
5.0
Thanks alot
Next Articles
- MedImmune: FluMist Introduction Vrio Analysis
- Mindray Medical International Limited: Going Global From China Vrio Analysis
- I've Got Rhythm: Selling Cardiac Rhythm Management Devices Vrio Analysis
- GE Healthcare India (B): The Product Innovation Journey Vrio Analysis
- Cialis Lifecycle Management: Lilly's BPH Dilemma Vrio Analysis
- Merck Medco: Vertical Integration In The Pharmaceutical Industry Vrio Analysis
- Gilead: Hepatitis C Access Strategy (A) Vrio Analysis
- Population Services International: The Social Marketing Project In Bangladesh, Video Vrio Analysis
- Glaxo And Zantac: The Life, Times, And Near Death Of The World's Best Selling Drug Vrio Analysis
- Synthes Vrio Analysis
Previous Articles
- Nin Jiom: Selling Traditional Chinese Medicine In Modern Hong Kong Vrio Analysis
- Pharmaceutical Switching Vrio Analysis
- Fighting AIDS And Pricing Drugs Vrio Analysis
- Med Mart: Transitioning The Business Model (A) Vrio Analysis
- ZS Associates: Sales Force Sizing Vrio Analysis
- 3M Chile: Health Care Products (B) Vrio Analysis
- Marketing Antidepressants: Prozac And Paxil, Spanish Version Vrio Analysis
- Dendrite International Vrio Analysis
- Medi Cult: Pricing A Radical Innovation Vrio Analysis
- Shaklee Corporation: Corporate Social Responsibility Vrio Analysis
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire Case48 with BIG enough reputation.
Our Guarantees
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!